CHICAGO — In patients with heterozygous familial hypercholesterolemia with high LDL despite being on optimal medical therapy, obicetrapib greatly lowered LDL levels compared with placebo, according to the results of the BROOKLYN trial. The phase 3 BROOKLYN trial, presented at the American Heart Association Scientific Sessions, included 354 patients diagnosed with heterozygous familial
Primary graft dysfunction (PGD) is a complication of lung transplantation that continues to cause significant morbidity. The Th2 immune response has been shown to counteract…
Geoffrey D. Barnes, MD, MSc, FACC
The fourth annual Precision Genomics Collaboratory Retreat will be held on December 13, 2024. This is a day-long event in the Trent Semans Center Great…
Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene and is characterized by skeletal and cardiac muscle disease. The progression of skeletal…
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a risk factor for cardiovascular disease. However, whether family members of individuals with MASLD also share an…
BACKGROUND: In October 2018, the US heart transplant (HT) allocation system was revised giving patients with left ventricular assist device (LVAD) intermediate priority status. Few…
This workshop will assess current state of knowledge on blood pressure assessment in clinical practice and clinic-based research.
BACKGROUND: DSP cardiomyopathy is a distinct subset of arrhythmogenic cardiomyopathy, reported primarily in adults, that has predominantly left ventricular involvement and features of myocarditis. Clinical…
There’s no “silver bullet” for this problem, which is largely driven by clinical inertia, but some efforts are chipping away at it.
DNA damage response plays a critical role in heart failure, including dilated cardiomyopathy (DCM), and assessment of myocardial DNA damage can predict treatment response and…
